ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.487,59
-0,61%
S&P 500
5.646,86
0,28%
Dow Jones
40.403,06
0,48%
Euro vs US Dollar
1,08726
-0,25%
Bitcoin
63.872,61
-1,49%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. AstraZeneca PLC (AZN)

  7. AstraZeneca PLC (AZN) News

AZN

AstraZeneca (AZN)

AstraZeneca PLC
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:AZN
DatumZeitQuelleÜberschriftSymbolFirma
26/10/202213h00Business WireCapivasertib plus FASLODEX® (fulvestrant) significantly improved progression-free survival vs. FASLODEX in CAPItello-291 Phase III trial in advanced HR-positive breast cancerNASDAQ:AZNAstraZeneca PLC
26/10/202208h45Dow Jones NewsAstraZeneca Says Capivasertib Phase 3 Trial Met Primary EndpointsNASDAQ:AZNAstraZeneca PLC
26/10/202200h42Dow Jones NewsADRs End Mostly Higher, AstraZeneca and atai Life Sciences Trade ActivelyNASDAQ:AZNAstraZeneca PLC
25/10/202212h32Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
25/10/202208h47Dow Jones NewsAstraZeneca's Fasenra Treatment Passed One of Two Endpoints in TrialNASDAQ:AZNAstraZeneca PLC
24/10/202213h12Business WireIMJUDO® (tremelimumab) in Combination With IMFINZI® (durvalumab) Approved in the US for Patients With Unresectable Liver CancerNASDAQ:AZNAstraZeneca PLC
24/10/202213h02Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
24/10/202208h50Dow Jones NewsAstraZeneca Imjudo-Imfinzi Combination Approved by FDA to Treat Inoperable Liver CancerNASDAQ:AZNAstraZeneca PLC
20/10/202215h00Business WireAstraZeneca Announces Winners of Fourth Annual Cancer Community AwardsNASDAQ:AZNAstraZeneca PLC
18/10/202213h30GlobeNewswire Inc.Ikena Oncology Provides Research & Development Update on IK-930 Program Targeting the Hippo PathwayNASDAQ:AZNAstraZeneca PLC
12/10/202213h00Business WireAlexion aims to advance NMOSD treatment landscape with exceptional ULTOMIRIS® (ravulizumab-cwvz) efficacy data at ECTRIMS 2022NASDAQ:AZNAstraZeneca PLC
06/10/202217h00PR Newswire (US)HONEYWELL BEGINS PRODUCTION OF NEAR-ZERO GLOBAL-WARMING-POTENTIAL MEDICAL PROPELLANTNASDAQ:AZNAstraZeneca PLC
04/10/202200h29Dow Jones NewsADRs End Higher, ABB and AstraZeneca Trade ActivelyNASDAQ:AZNAstraZeneca PLC
03/10/202217h55Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
03/10/202217h20Dow Jones NewsLogicBio Therapeutics Shares Soar on Takeover by AstraZenecaNASDAQ:AZNAstraZeneca PLC
03/10/202213h57Dow Jones NewsAstraZeneca to Buy LogicBio Therapeutics for $68 MillionNASDAQ:AZNAstraZeneca PLC
03/10/202213h15Business WireAlexion, AstraZeneca Rare Disease to Acquire LogicBio® Therapeutics to Accelerate Growth in Genomic MedicineNASDAQ:AZNAstraZeneca PLC
30/09/202212h24Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
27/09/202212h06Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
27/09/202212h03Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
26/09/202218h11Dow Jones NewsAstrazeneca Currently Down 10 Straight Days, on Track for Longest Losing Streak Since October 2004 -- Data TalkNASDAQ:AZNAstraZeneca PLC
26/09/202208h48Dow Jones NewsGSK PLC Names Julie Brown as New CFO; Iain Mackay to Retire in MayNASDAQ:AZNAstraZeneca PLC
24/09/202200h41Dow Jones NewsADRs End Lower, Alibaba and AstraZeneca Trade ActivelyNASDAQ:AZNAstraZeneca PLC
23/09/202208h42Dow Jones NewsAstraZeneca Gets EU Approval for Ultomiris DrugNASDAQ:AZNAstraZeneca PLC
22/09/202212h49Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
22/09/202209h09Dow Jones NewsAstraZeneca, Merck's Lynparza Treatment for Advanced Ovarian Cancer Approved in ChinaNASDAQ:AZNAstraZeneca PLC
21/09/202212h19Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
21/09/202208h50Dow Jones NewsAstraZeneca's Tezspire Gets EU Approval for Severe Asthma TreatmentNASDAQ:AZNAstraZeneca PLC
20/09/202212h17Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
20/09/202208h42Dow Jones NewsAstraZeneca's Evusheld Drug Approved by EU for Covid-19 TreatmentNASDAQ:AZNAstraZeneca PLC
 Showing the most relevant articles for your search:NASDAQ:AZN

Kürzlich von Ihnen besucht

BOV
EZTCG146
EZTCG146 Ex:14,6
TSXV
FEX
Fjordland Exploration
LSE
EIMI
Ishrc Em Imi
USOTC
VYCO
Vycor Medical (QB)
BIT
P1HXA8
BNP Paribas Issuance
TSX
DATA
Evolve Cloud Computing
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten